MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF

Cell Cycle

Volumn 11, Issue 11, 2012, Pages 2137-2145

  Zou, Chao ^a   Xu, Qing ^b   Mao, Feng ^c   Li, Dan ^a   Bian, Chuanxiu ^b   Liu, Ling Zhi ^d   Jiang, Yue ^d   Chen, Xiaona ^a   Qi, Yanting ^d   Zhang, Xiaolong ^a   Wang, Xuejing ^c   Sun, Qiang ^c   Kung, Hsiang Fu ^a,e   Lin, Marie C ^a,f   Dress, Andreas ^a,g   Wardle, Fiona ^a,h   Jiang, Bing Hua ^b,d   Lai, Lihui ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Breast cancer; miR 145; N RAS; VEGF A

Indexed keywords

MICRORNA 145; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE N RAS; TRANSCRIPTION REGULATION; TUMOR GROWTH;

EID: 84861861100     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20598     Document Type: Article

References (42)

1. Mohinta S, Wu H, Chaurasia P, Watabe K. Wnt pathway and breast cancer. Front Biosci 2007; 12:4020-33; PMID:17485355; http://dx.doi.org/10.2741/2368.
2. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007; 26:2502-6; PMID:17016428; http://dx.doi.org/10.1038/sj.onc.1210032.
3. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19:877-90; PMID:15833914; http://dx.doi.org/10.1101/gad.1295405.
4. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70; PMID:16103053; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783.
5. Simin K, Wu H, Lu L, Pinkel D, Albertson D, Cardiff RD, et al. pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol 2004; 2:22; PMID:14966529; http://dx.doi.org/10.1371/journal.pbio.0020022.
6. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5; PMID:15372042; http://dx.doi.org/10.1038/nature02871.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702.
8. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15:563-8; PMID:16099643; http://dx.doi.org/10.1016/j. gde.2005.08.005.
9. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102:883-91; PMID:20160723; http://dx.doi.org/10.1038/sj.bjc.6605570.
10. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010; 5:8836; PMID:20098684; http://dx.doi.org/10.1371/journal.pone.0008836.
11. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012; 3:44-57; PMID:22294552.
12. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127:2804-14; PMID:21351259; http://dx.doi.org/10.1002/ijc.25284.
13. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34:1461-6; PMID:19360360.
14. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40:761-74; PMID:21917858; http://dx.doi.org/10.1093/nar/ gkr730.
15. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2011; 2:29-42; PMID:21378409.
16. Qu C, Liang Z, Huang J, Zhao R, Su C, Wang S, et al. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle 2012; 11:785-96; PMID:22374676; http://dx.doi.org/10.4161/cc. 11.4.19228.
17. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29:1073-84; PMID:19915607; http://dx.doi.org/10.1038/onc.2009.395.
18. Lai VK, Ashraf M, Jiang S, Haider K. MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 2012; 11:767-77; PMID:22374674; http://dx.doi.org/10.4161/cc.11.4.19211.
19. Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramírez CM, Chamorro-Jorganes A, et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012; 11:922-33; PMID:22333591; http://dx.doi.org/10. 4161/cc.11.5.19421.
20. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70:378-87; PMID:19996288; http://dx.doi.org/10.1158/0008-5472.CAN-09-2021.
21. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2 and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137:647-58; PMID:19409607; http://dx.doi.org/10.1016/j.cell. 2009.02.038.
22. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012; 106:366-74; PMID:22108519; http://dx.doi.org/10.1038/bjc.2011.520.
23. Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011; 8:125-31; PMID:21289483; http://dx.doi.org/10.4161/rna.8.1.14259.
24. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feedforward pathway. Genes Dev 2010; 24:2754-9; PMID:21159816; http://dx.doi.org/10.1101/gad.1950610.
25. Sachdeva M, Liu Q, Cao J, Lu Z, Mo YY. Negative regulation of miR-145 by C/EBPâ through the Akt pathway in cancer cells. Nucleic Acids Res 2012; (Epub ahead of print); PMID:22495929; http://dx.doi.org/10.1093/nar/gks324.
26. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6:507-18; PMID:19636328; http://dx.doi.org/10.1038/nrclinonc.2009.110.
27. Jiang ZY, He Z, King BL, Kuroki T, Opland DM, Suzuma K, et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003; 278:31964-71; PMID:12775712; http://dx.doi.org/10.1074/jbc.M303314200.
28. Stearns M, Tran J, Francis MK, Zhang H, Sell C. Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res 2005; 65:2085-8; PMID:15781617; http://dx.doi.org/10.1158/0008-5472.CAN-04-4100.
29. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282:32582-90; PMID:17827156; http://dx.doi.org/10.1074/jbc.M702806200.
30. La Rocca G, Shi B, Badin M, De Angelis T, Sepp-Lorenzino L, Baserga R. Growth inhibition by microRNAs that target the insulin receptor substrate-1. Cell Cycle 2009; 8:2255-9; PMID:19502786; http://dx.doi.org/10.4161/cc.8.14. 9026.
31. Götte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29:6569-80; PMID:20818426; http://dx.doi.org/10. 1038/onc.2010.386.
32. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145 participates with Tp53 in a death-promoting regulatory loop and targets estrogen receptoralpha in human breast cancer cells. Cell Death Differ 2010; 17:246-54; PMID:19730444; http://dx.doi.org/10.1038/cdd.2009.117.
33. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:507-17; PMID:21270527; http://dx.doi.org/10.4161/cc.10.3.14754.
34. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38:1060-5; PMID:16878133; http://dx.doi.org/10.1038/ng1855.
35. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 2007; 104:20350-5; PMID:18077375; http://dx.doi.org/10.1073/pnas. 0706901104.
36. Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008; 14:382-93; PMID:18977327; http://dx.doi.org/10.1016/j.ccr.2008.10.005.
37. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-56; PMID:20173740.
38. Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010; 70:2675-85; PMID:20233879; http://dx.doi.org/10. 1158/0008-5472.CAN-09-2448.
39. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107:6334-9; PMID:20308559; http://dx.doi.org/10.1073/pnas. 0911082107.
40. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14:2348-60; PMID:18812439; http://dx.doi.org/10.1261/rna.1034808.
41. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol-3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97:1749-53; PMID:10677529; http://dx.doi.org/10.1073/pnas.040560897.
42. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011; 17:1722-30; PMID:21350001; http://dx.doi.org/10.1158/1078-0432.CCR-10- 1800.